Compliance Software

The FDA expects organizations to have full visibility and control over their processes

Available from Dassault Systèmes BIOVIA

The FDA expects organizations to have full visibility and control over their processes

Content Summary

Expectations include:
• Understanding products and processes in order to implement Quality by Design (QbD) into product development
• Delivery of quality metrics for risk-based inspection schedules as proposed by a new quality metrics program
• Shared responsibility for products manufactured by their Contract Manufacturing Organizations (CMOs)
• Drive improvements in manufacturing technology, product quality and safety - reducing recalls and mitigating drug shortages

Access this content

Choose an option below

Your content has been opened.

Please verify you are a human before downloading this content.

Please verify you are a human before adding this content to your library.


Register to access this content


Verify your email to access this content

Code sent. Enter it in the modal

Your content has been opened.

Please verify you are a human before opening this content.

Why do I need to verify I’m human?

Please verify you are a human before opening this content.

Your content has been opened.

Please verify you are a human before downloading this content.

Please verify you are a human before opening this content.

The content will open in a new window. You may need to allow popups for this site.